Table 2 Baseline characteristics
The primary cohort (n = 1401) | The validation cohort (n = 600) | The primary cohort (n = 1401) | The validation cohort(n = 600) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Age, n, % | Chemotherapy, n, % | ||||||||
< 70 | 800 | 57.10% | 366 | 61.0% | Yes | 646 | 46.11% | 300 | 50.0% |
≥ 70 | 601 | 42.90% | 234 | 39.0% | No/unknown | 755 | 53.89% | 300 | 50.0% |
Sex, n, % | Radiotherapy, n, % | ||||||||
Female | 671 | 47.89% | 288 | 48.0% | Yes | 282 | 20.12% | 120 | 20.0% |
Male | 730 | 52.11% | 353 | 58.8% | No | 1199 | 85.58% | 480 | 80.0% |
Marital status, n, % | |||||||||
Married | 863 | 61.60% | 353 | 58.8% | |||||
Othersa | 538 | 38.40% | 247 | 41.2% | |||||
AJCC 7th, n, % | |||||||||
Race, n, % | 0 | 222 | 15.85% | 98 | 16.3% | ||||
Others | 151 | 10.78% | 59 | 9.8% | IA | 98 | 7.00% | 20 | 3.3% |
Black | 1096 | 78.23% | 475 | 79.2% | IB | 100 | 7.14% | 41 | 6.8% |
White | 154 | 10.99% | 66 | 11.0% | IIA | 141 | 10.06% | 66 | 11.0% |
0.00% | IIB | 260 | 18.56% | 101 | 16.8% | ||||
Location, n, % | III | 138 | 9.85% | 74 | 12.3% | ||||
Head | 762 | 54.39% | 339 | 56.5% | IV | 442 | 31.55% | 200 | 33.3% |
Body or tail | 387 | 27.62% | 160 | 26.7% | |||||
Othersb | 353 | 25.20% | 101 | 16.8% | AJCC 8th, n, % | ||||
0 | 222 | 15.85% | 98 | 16.3% | |||||
Grade, n, % | IA | 113 | 8.07% | 33 | 5.5% | ||||
Highc | 191 | 13.63% | 78 | 13.0% | IB | 107 | 7.64% | 48 | 8.0% |
Othersd | 1210 | 86.37% | 522 | 87.0% | IIA | 119 | 8.49% | 46 | 7.7% |
IIB | 168 | 11.99% | 66 | 11.0% | |||||
ELN, n, % | III | 230 | 16.42% | 109 | 18.2% | ||||
< 15 | 1012 | 72.23% | 448 | 74.7% | IV | 442 | 31.55% | 200 | 33.3% |
≥ 15 | 389 | 27.77% | 152 | 25.3% | |||||
AJCC modified, n, % | |||||||||
Extend, n, % | 0 | 222 | 15.85% | 98 | 16.3% | ||||
Inside | 666 | 47.54% | 275 | 45.8% | IA | 113 | 8.07% | 33 | 5.5% |
Beyond | 735 | 52.46% | 325 | 54.2% | IB | 226 | 16.13% | 94 | 15.7% |
IIA | 168 | 11.99% | 66 | 11.0% | |||||
Surgery, n, % | IIB | 92 | 6.57% | 35 | 5.8% | ||||
Yes | 862 | 61.53% | 343 | 57.2% | III | 138 | 9.85% | 74 | 12.3% |
No | 539 | 38.47% | 257 | 42.8% | IV | 442 | 31.55% | 200 | 33.3% |